WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has started construction of an integrated biologics conjugate solution center in Wuxi city, China.
The $20 million 6000 sq m facility will be operational in 2019 and provide integrated solutions from concept to commercialisation for biologics conjugates including antibody-drug conjugates (ADCs) and other protein conjugates.
ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic drug and are becoming emerging treatments of targeted tumour therapy. WuXi Biologics plans to build a site providing world-class ADC R&D and manufacturing, which will meet US, EU and Chinese cGMP standards.
“I am very excited about this new investment in ADCs,” Dr Chris Chen, CEO of WuXi Biologics said.
“In collaboration with the chemistry division of WuXi AppTec Group, WuXi Biologics is one of the few global companies that can provide the one-stop service to global partners for antibodies, small molecule payloads, ADCs drug substance and drug products. Our vision is to empower any global partners to develop any ADC to benefit patients,” he concluded.
WuXi Biologics, is an affiliate of WuXi AppTec.
